Boehringer Ingelheim: Investigator-Initiated Studies (IIS)

From Boehringer Ingelheim Cares Foundation Inc

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) is dedicated to supporting innovative projects and programs that enhance the knowledge and understanding of diseases and technological advancements. Their commitment is toward advancing scientific awareness and technologies for public health and welfare in various therapeutic areas of interest. They aim to further scientific progress while ensuring that the projects they support maintain independent control over their goals and dissemination of knowledge.

Type of Support

Overview

The Investigator-Initiated Studies (IIS) program by Boehringer Ingelheim supports independent research initiatives, emphasizing the exploration and proof of concept across various therapeutic areas without directly funding the Principal Investigator's salary. These areas include:

Cardio-Renal-Metabolic systems, with a specific interest in the exploration of empagliflozin's effects.
Mental Health, focusing on schizophrenia, post-traumatic stress disorder, the use of digital therapeutics in psychiatry, and major depressive disorder, aiming to improve patient assessment, diagnosis, treatment landscape understanding, and disease progression evaluation.
Dermatology, particularly in studying Generalized Pustular Psoriasis (GPP), to understand the natural disease course, impact of comorbidities, development of patient-reported outcome tools, treatment limitations, pathogenesis, prevalence, and patient management strategies. Boehringer Ingelheim may offer financial support and/or medication for approved studies but does not act as the regulatory sponsor. Applications for support must be submitted through an online process, with the company open to exploring various research interests within the specified therapeutic areas.